NASDAQ
BMRN
Last Price
US $58.64
KEY FIGURES
MKT CAP
$11.3B
EPS
TTM
$1.40
PEG
TTM
N/M
P/E
TTM
42.00x
P/S
TTM
3.48x
YIELD
0.00%
GROWTH
Revenue Y/Y
Profit margin
Current Ratio
Capital Returns
4.41%
Return on equity
ROIC: 3.92%
Valuation History
42.2X
Price to Earnings
EV/EBITDA: 22.1X
Cash flow
Profit margin
11.60%
(FY vs FY)
EBITDA Y/Y
46.93%
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $58.64
—
Default assumptions
EBITDA Multiple
Fair Value
Market $58.64
-58.49%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
BioMarin Pharmaceutical Inc. cash flow to debt ratio of 128.80% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.
Financial stability - Healthy cash flow growth.
BioMarin Pharmaceutical Inc.'s free cash flow has increased 52.49% from $475.42M last year to $724.96M, signaling increasing performance
Financial stability - Healthy debt to equity ratio.
BioMarin Pharmaceutical Inc.'s debt to equity ratio is 0.23, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial risk - Healthy debt to equity ratio development.
BioMarin Pharmaceutical Inc.'s debt has increased relative to shareholder equity from 0.11 last year to 0.23 today, signaling weakened financials
Financial stability - Net debt/EBITDA.
BioMarin Pharmaceutical Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
BioMarin Pharmaceutical Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial risk - Profit margin growth.
BioMarin Pharmaceutical Inc.'s profit margin has decreased (-44.58%) in the last year from 14.96% to 8.29%, signaling decreasing performance
Financial stability - Short term assets vs short term liabilities.
BioMarin Pharmaceutical Inc.'s short-term assets of $3.95G exceed its short-term liabilities of $759.03M
Decreasing performance - ROA.
BioMarin Pharmaceutical Inc.'s return on assets of 3.13% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
BioMarin Pharmaceutical Inc.'s return on equity of 4.41%, is lower than 15.00%, indicating bad performance
Increasing performance - Earnings quality.
BioMarin Pharmaceutical Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation
Increasing performance - Earnings stability.
BioMarin Pharmaceutical Inc. had positive net income in 4.00 out of 5 years, indicating stable and consistent earnings
Increasing performance - Free cash flow.
BioMarin Pharmaceutical Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
BioMarin Pharmaceutical Inc. has a free cash flow yield of 6.40%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Decreasing performance - Healthy earnings growth.
BioMarin Pharmaceutical Inc.'s yearly earnings has decreased -18.26% since last year from $426.86M to $348.90M, signaling decreasing performance
Decreasing performance - Healthy revenue growth.
BioMarin Pharmaceutical Inc.'s yearly revenue has decreased -100.00% since last year from $2.85G to $0.00, signaling decreasing performance
Decreasing performance - ROIC.
ROIC 3.92% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
BioMarin Pharmaceutical Inc.'s 3-year revenue CAGR of 15.40% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
BioMarin Pharmaceutical Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance
Increasing performance - ROE consistency.
BioMarin Pharmaceutical Inc. had positive ROE in 4.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
BioMarin Pharmaceutical Inc. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
BioMarin Pharmaceutical Inc. has an earnings yield of 2.38%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings
Overvalued - EBITDA valuation.
BioMarin Pharmaceutical Inc. is overvalued relative to its fair value price of 24.34 based on EBITDA multiple model
Undervalued - EV/EBITDA.
BioMarin Pharmaceutical Inc. has an EV/EBITDA ratio of 18.62x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Overvalued - PEG ratio value.
BioMarin Pharmaceutical Inc. has no meaningful EPS growth rate; PEG ratio cannot be computed.
Undervalued - P/B ratio.
BioMarin Pharmaceutical Inc. has a price-to-book ratio of 1.82x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
BioMarin Pharmaceutical Inc. has a price-to-sales ratio of 3.48x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue